surmount 1 tirzepatide In an earlier analysis of the SURMOUNT-1 trial, (a dual glucose-dependent insulinotropic polypeptide [GIP] and glucagon-like peptide-1 [GLP-1] receptor agonist) was shown to provide substantial and sustained reductions in body weight Tirzepatide SURMOUNT-1 three year efficacy
Pay in 4 interest-free payments of $6.95 Learn more
Shipping Estimate
USA
- USA
- CAN
- USA
- CAN
Ships within 48 hours · Estimated delivery Jul 31 - Aug 5
![surmount 1 tirzepatide In an earlier analysis of the SURMOUNT-1 trial, (a dual glucose-dependent insulinotropic polypeptide [GIP] and glucagon-like peptide-1 [GLP-1] receptor agonist) was shown to provide substantial and sustained reductions in body weight Tirzepatide SURMOUNT-1 three year efficacy](https://pbs.twimg.com/media/GbkrERnWYAAToeK.jpg)
![surmount 1 tirzepatide In an earlier analysis of the SURMOUNT-1 trial, (a dual glucose-dependent insulinotropic polypeptide [GIP] and glucagon-like peptide-1 [GLP-1] receptor agonist) was shown to provide substantial and sustained reductions in body weight Tirzepatide SURMOUNT-1 three year efficacy](https://www.researchgate.net/publication/399980619/figure/fig4/AS:11431281878422675@1769101323716/Overview-of-key-tirzepatide-clinical-trials-and-their-cardiovascular-and-metabolic.png)
![surmount 1 tirzepatide In an earlier analysis of the SURMOUNT-1 trial, (a dual glucose-dependent insulinotropic polypeptide [GIP] and glucagon-like peptide-1 [GLP-1] receptor agonist) was shown to provide substantial and sustained reductions in body weight Tirzepatide SURMOUNT-1 three year efficacy](https://cdn.ncbi.nlm.nih.gov/pmc/blobs/832c/12326891/91371dd0ccec/DOM-27-5064-g001.jpg)



















